Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes.

Minejima E, Mai N, Bui N, Mert M, She RC, Nieberg P, Spellberg B, Wong-Beringer A.

Clin Infect Dis. 2019 Apr 5. pii: ciz257. doi: 10.1093/cid/ciz257. [Epub ahead of print]

PMID:
30949675
2.

Antimicrobial Stewardship Opportunities in Patients with Bacteremia Not Identified by BioFire FilmArray.

Ny P, Ozaki A, Pallares J, Nieberg P, Wong-Beringer A.

J Clin Microbiol. 2019 Apr 26;57(5). pii: e01941-18. doi: 10.1128/JCM.01941-18. Print 2019 May.

PMID:
30814265
3.

Utility of qSOFA score in identifying patients at risk for poor outcome in Staphylococcus aureus bacteremia.

Minejima E, Delayo V, Lou M, Ny P, Nieberg P, She RC, Wong-Beringer A.

BMC Infect Dis. 2019 Feb 13;19(1):149. doi: 10.1186/s12879-019-3770-4.

4.

Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes.

Jorgensen SCJ, Yeung SL, Zurayk M, Terry J, Dunn M, Nieberg P, Pallares J, Wong-Beringer A.

Open Forum Infect Dis. 2018 May 2;5(6):ofy101. doi: 10.1093/ofid/ofy101. eCollection 2018 Jun.

5.

Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Humphries RM, Hindler JA, Magnano P, Wong-Beringer A, Tibbetts R, Miller SA.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01633-17. doi: 10.1128/JCM.01633-17. Print 2018 Mar.

6.

Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01858-17. doi: 10.1128/AAC.01858-17. Print 2017 Dec.

7.

Clinically significant bacteria/pyuria-the author responds.

Jorgensen S, Wong-Beringer A.

Am J Emerg Med. 2017 Oct;35(10):1561. doi: 10.1016/j.ajem.2017.07.060. Epub 2017 Jul 21. No abstract available.

PMID:
28760381
8.

Risk factors for early return visits to the emergency department in patients with urinary tract infection.

Jorgensen S, Zurayk M, Yeung S, Terry J, Dunn M, Nieberg P, Wong-Beringer A.

Am J Emerg Med. 2018 Jan;36(1):12-17. doi: 10.1016/j.ajem.2017.06.041. Epub 2017 Jun 21.

PMID:
28655424
9.

Emergency Department Urinary Antibiograms Differ by Specific Patient Group.

Jorgensen S, Zurayk M, Yeung S, Terry J, Dunn M, Nieberg P, Wong-Beringer A.

J Clin Microbiol. 2017 Sep;55(9):2629-2636. doi: 10.1128/JCM.00481-17. Epub 2017 Jun 14.

10.

Staphylococcus aureus Bacteremia in Patients not Meeting Sepsis Criteria: Clinical Features, Host Immune Response and Outcomes.

Salas DE, Minejima E, Wu J, Fang C, Wang J, She R, Nieberg P, Wong-Beringer A.

J Clin Med Ther. 2017;2(4). pii: 27. Epub 2017 Nov 20.

11.

Wavelength-normalized spectroscopic analysis of Staphylococcus aureus and Pseudomonas aeruginosa growth rates.

McBirney SE, Trinh K, Wong-Beringer A, Armani AM.

Biomed Opt Express. 2016 Sep 14;7(10):4034-4042. eCollection 2016 Oct 1.

12.
13.

Implementation of rapid diagnostics with antimicrobial stewardship.

Minejima E, Wong-Beringer A.

Expert Rev Anti Infect Ther. 2016 Nov;14(11):1065-1075. Epub 2016 Sep 19. Review.

PMID:
27599796
14.

Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.

Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, Bauer K, Goff DA, Adamson R, Leuthner K, Virata MD, McKinnell JA, Chaudhry SB, Eskandarian R, Lodise T, Reyes K, Zervos MJ.

Clin Ther. 2016 Jan 1;38(1):16-30. doi: 10.1016/j.clinthera.2015.09.017. Epub 2015 Nov 14.

PMID:
26585355
15.

A Dysregulated Balance of Proinflammatory and Anti-Inflammatory Host Cytokine Response Early During Therapy Predicts Persistence and Mortality in Staphylococcus aureus Bacteremia.

Minejima E, Bensman J, She RC, Mack WJ, Tuan Tran M, Ny P, Lou M, Yamaki J, Nieberg P, Ho J, Wong-Beringer A.

Crit Care Med. 2016 Apr;44(4):671-9. doi: 10.1097/CCM.0000000000001465.

16.

Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.

Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME.

J Antimicrob Chemother. 2016 Jan;71(1):181-8. doi: 10.1093/jac/dkv301. Epub 2015 Oct 3.

17.

Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.

Ny P, Nieberg P, Wong-Beringer A.

Am J Infect Control. 2015 Oct 1;43(10):1076-80. doi: 10.1016/j.ajic.2015.06.008. Epub 2015 Jul 17.

PMID:
26190386
18.

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.

Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14. Epub 2015 May 11.

19.

Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment.

Minejima E, Lou M, Nieberg P, Wong-Beringer A.

BMC Infect Dis. 2014 May 10;14:252. doi: 10.1186/1471-2334-14-252.

20.

The use of oligonucleotide recombination to generate isogenic mutants of clinical isolates of Pseudomonas aeruginosa.

Agnello M, Wong-Beringer A.

J Microbiol Methods. 2014 Mar;98:23-5. doi: 10.1016/j.mimet.2013.11.014. Epub 2013 Dec 25.

21.

Microbicidal effects of α- and θ-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Tai KP, Kamdar K, Yamaki J, Le VV, Tran D, Tran P, Selsted ME, Ouellette AJ, Wong-Beringer A.

Innate Immun. 2015 Jan;21(1):17-29. doi: 10.1177/1753425913514784. Epub 2013 Dec 17.

22.

Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.

Sullivan E, Bensman J, Lou M, Agnello M, Shriner K, Wong-Beringer A.

Crit Care Med. 2014 Jan;42(1):48-56. doi: 10.1097/CCM.0b013e318298a86f.

PMID:
23963124
23.

Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.

Joo J, Yamaki J, Lou M, Hshieh S, Chu T, Shriner KA, Wong-Beringer A.

Clin Ther. 2013 Jul;35(7):995-1004. doi: 10.1016/j.clinthera.2013.05.018. Epub 2013 Jul 2.

PMID:
23829982
24.

Tigecycline induction of phenol-soluble modulins by invasive methicillin-resistant Staphylococcus aureus strains.

Yamaki J, Synold T, Wong-Beringer A.

Antimicrob Agents Chemother. 2013 Sep;57(9):4562-5. doi: 10.1128/AAC.00470-13. Epub 2013 Jul 1.

25.

Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa.

Agnello M, Wong-Beringer A.

PLoS One. 2012;7(8):e42973. doi: 10.1371/journal.pone.0042973. Epub 2012 Aug 8.

26.

Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins.

Yamaki J, Synold T, Wong-Beringer A.

Antimicrob Agents Chemother. 2011 Sep;55(9):4432-5. doi: 10.1128/AAC.00122-11. Epub 2011 Jun 13.

27.

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.

Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A.

Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83. doi: 10.1128/AAC.00173-11. Epub 2011 May 16.

28.

Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?

Yamaki J, Lee M, Shriner KA, Wong-Beringer A.

Diagn Microbiol Infect Dis. 2011 May;70(1):124-30. doi: 10.1016/j.diagmicrobio.2010.12.003. Epub 2011 Mar 9.

PMID:
21392923
29.

Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.

Wong-Beringer A, Joo J, Tse E, Beringer P.

Int J Antimicrob Agents. 2011 Feb;37(2):95-101. doi: 10.1016/j.ijantimicag.2010.10.013. Epub 2010 Dec 3. Review.

PMID:
21130609
30.

Regulatory oversight and safety of probiotic use.

Venugopalan V, Shriner KA, Wong-Beringer A.

Emerg Infect Dis. 2010 Nov;16(11):1661-5. doi: 10.3201/eid1611.100574.

31.

Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.

Burgess DS, Slain D, Mohr J, Wong-Beringer A, Destache C, Suda K.

Clin Infect Dis. 2010 Sep 15;51(6):753; author reply 754-5. doi: 10.1086/655957. No abstract available.

PMID:
20731568
32.

A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.

Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A.

J Antimicrob Chemother. 2010 Aug;65(8):1765-70. doi: 10.1093/jac/dkq216. Epub 2010 Jun 16.

PMID:
20554567
33.

An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse.

Wong-Beringer A, Nguyen LH, Lee M, Shriner KA, Pallares J.

Pharmacotherapy. 2009 Jun;29(6):736-43. doi: 10.1592/phco.29.6.736.

PMID:
19476424
34.

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A.

Int J Antimicrob Agents. 2008 Nov;32(5):378-85. doi: 10.1016/j.ijantimicag.2008.05.007. Epub 2008 Aug 12.

PMID:
18701261
35.

Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.

Nguyen LH, Hsu DI, Ganapathy V, Shriner K, Wong-Beringer A.

J Antimicrob Chemother. 2008 Mar;61(3):714-20. doi: 10.1093/jac/dkm510. Epub 2008 Jan 25.

PMID:
18222951
36.

Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.

Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J.

Clin Microbiol Infect. 2008 Apr;14(4):330-6. doi: 10.1111/j.1469-0691.2007.01939.x. Epub 2008 Jan 11.

37.

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A.

Arch Intern Med. 2006 Oct 23;166(19):2138-44.

PMID:
17060545
38.

Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice.

Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL.

Chest. 2005 Nov;128(5):3711-6.

PMID:
16304338
39.

Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.

Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A.

Antimicrob Agents Chemother. 2005 Sep;49(9):3676-81.

40.

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.

Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A.

J Antimicrob Chemother. 2005 Apr;55(4):535-41. Epub 2005 Feb 22.

PMID:
15728150
41.
42.

Caspofungin: a potential cause of reversible severe thrombocytopenia.

Lynch J, Wong-Beringer A.

Pharmacotherapy. 2004 Oct;24(10):1408-11.

PMID:
15628837
43.

Treating serious infections: focus on cefepime.

Wong-Beringer A.

Pharmacotherapy. 2004 Dec;24(12 Pt 2):216S-23S. Review.

PMID:
15585451
44.

Systemic antifungal therapy: new options, new challenges.

Wong-Beringer A, Kriengkauykiat J.

Pharmacotherapy. 2003 Nov;23(11):1441-62. Review.

PMID:
14620391
45.

Applying patient selection criteria for drotrecogin alfa therapy in practice.

Wong-Beringer A, Liao C, Nguyen M, Pallares J.

Am J Health Syst Pharm. 2003 Jul 1;60(13):1345-52. No abstract available.

PMID:
12901037
46.

Pneumococcal vaccination in hospitalized elderly patients: role of the pharmacist.

Wong-Beringer A, Brodetsky E, Quist R.

Pharmacotherapy. 2003 Feb;23(2):199-208.

PMID:
12587809
47.

Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.

Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, Quinn JP, Bush K.

Clin Infect Dis. 2002 Jan 15;34(2):135-46. Epub 2001 Dec 4.

PMID:
11740699
48.

Implementing a program for switching from i.v. to oral antimicrobial therapy.

Wong-Beringer A, Nguyen KH, Razeghi J.

Am J Health Syst Pharm. 2001 Jun 15;58(12):1146-9.

PMID:
11449860
49.
50.

Fluconazole-induced agranulocytosis with eosinophilia.

Wong-Beringer A, Shriner K.

Pharmacotherapy. 2000 Apr;20(4):484-6.

PMID:
10772380

Supplemental Content

Loading ...
Support Center